Eines der Hauptziele von Life4me+ — ist neue Fälle von HIV und anderen STIs, Hepatitis C und Tuberkulose zu verhindern.

Die App hilft, eine Kommunikation zwischen Ärzten und HIV-positiven Menschen aufzubauen. Die App erlaubt Ihnen, einen Zeitplan für Ihre Medikamenteneinnahme bequem zu organisieren – dies geschieht über eine für Dritte nicht nachvollziehbare und personalisierte Erinnerung.

Zurück
8 September 2017, 09:58
3675

Gilead will donate $ 1 million to HIV organizations affected by hurricanes Harvey and Irma

Gilead will donate $ 1 million to HIV organizations affected by hurricanes Harvey and Irma - Bild 1

Yesterday, on 7, September, at the opening ceremony of the 21st annual US AIDS conference in Washington, DC, the pharmaceutical company Gilead Sciences announced the creation of a special charity fund to donate $ 1 million to help HIV service organizations affected by the hurricanes Harvey and Irma.

The statement was made at the opening of the plenary session of the USCA - 2017, attended by representatives of communities affected by the elements of the state.

Coordination of the fund will focus on AIDS United and the National Council for the Fight against AIDS (NMAC).

"The generous contribution of Gilead is of great importance to people living with HIV and to the organizations that serve them, who were devastated by Hurricanes Harvey and Irma," said NMAC Executive Director Paul Kawata. "We expect that we will reach the most needy organizations as soon as possible".

"For states that have suffered from hurricanes and who have faced a long process of recovery, it is more important than ever that services provided by HIV organizations continue to reach those in need," said Gregg H. Alton, Executive Vice President, Corporate and Medical Affairs Gilead.

We add that in addition to the Gilead donation, $ 150,000 for the support of HIV-service organizations in the states that suffered destruction was allocated by AIDS United, and another $ 20,000 by the Florida Campbell Foundation, which supports clinical research in the field of HIV.

Autor*in: Narek Karamjan

Teilen Sie in sozialen Netzwerken